
INDEPENDENT AUDITORS' REPORT

**To the Members of
Mono Pharmacare Limited**

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the accompanying standalone financial statements of **Mono Pharmacare Limited** ("the Company"), which comprise the Balance Sheet as at 31st March, 2023, the Statement of Profit and Loss and Cash Flow Statement for the year then ended and a summary of the significant accounting policies and other explanatory information.


In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2023 and its Profit and its cash flows for the year ended on that date.

Basis for opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Statements* section of our report. We are independent of the Company in accordance with the *Code of Ethics* issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Information Other than the Standalone Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Annual Report, but does not



include the financial statements and our Auditor's Report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to Report that fact. We have nothing to Report in this regard.

Responsibility of Management and Those Charge with Governance for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the financials position, financial performance, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India including the other accounting Standards specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities, selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial Reporting process.




Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our Auditor's Report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Auditor's Report. However, future events or conditions may cause the Company to cease to continue as a going concern.



- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our Auditor's Report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our Report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of Section 143(11) of the Act, we give in "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order.

Further to our comments in "Annexure A", as required by Section 143(3) of the Act, we Report that:

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit.
- b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- c) The Balance Sheet, the Statement of Profit and Loss and the Statement of Cash Flow dealt with by this Report are in agreement with the relevant books of account.



- d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e) On the basis of the written representations received from the directors as on March 31, 2023 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2023 from being appointed as a director in terms of Section 164 (2) of the Act.
- f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B". Our report expresses an unmodified opinion on the adequacy opinion on the adequacy and operating effectiveness of the Company's internal financial control over financial reporting.
- g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:
- i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company has not entered into any long term contracts including derivative contracts for which there were any material foreseeable losses, as required under the applicable law or Indian Accounting Standards.
 - iii. There has been no delay in transferring the amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.
 - iv. (a) The Management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person or entity, including foreign entity ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;



(b) The Management has represented , that, to the best of its knowledge and belief, no funds have been received by the Company from any person or entity, including foreign entity ("Funding Parties"), with the understanding , whether recorded in writing or otherwise, that the Company shall, whether , directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries ") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(c) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11 (e), as provided under (a) and (b) above, contain any material misstatement.

- v. The Company has not declared or paid any dividend during the year hence no compliance is required with Section 123 of the Companies Act 2013.



Place: Mumbai
Dated: August 7th, 2023

For KUMBHAT & CO.
Chartered Accountants
Firm Regn. No. 001609S

A handwritten signature in blue ink, appearing to read "Gaurang C. Unadkat".


Gaurang C. Unadkat
Partner

Mem.No. 131708
UDIN: 23131708BGWHGE8783

Annexure "A" to the Independent Auditor's Report

(Referred to in Paragraph 1 under the heading of "Report on Other Legal and Regulatory Requirements" of our report of even date)

- (i) In respect of the Company's Property, Plant and Equipment and Intangible Assets:
- (a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.
- (B) The Company has maintained proper records showing full particulars of intangible assets.
- (b) The Company has a phased program of physical verification of Property, Plant and Equipment so to cover all the assets which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. According to the information and explanations given to us, no material discrepancies were noticed on such verification.
- (c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of immovable properties (other than immovable properties where the Company is a lessee, and the lease agreements are duly executed in favour of the lessee) are held in the name of the Company.
- (d) The Company has not revalued any of its Property, Plant and Equipment and intangible assets during the year.
- (e) No proceedings have been initiated during the year or are pending against the Company as at March 31, 2023 for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and rules made thereunder.
- (ii) (a) As explained to us, the physical verification of inventory has been conducted by the Management in accordance with the phased programme of verification which, In our opinion, is reasonable and no material discrepancies were noticed on such verification and the discrepancies noticed on physical verification for each class of inventory have been properly dealt with in the books of accounts.



(b) The Company has been sanctioned working capital limits in excess of five crore rupees in aggregate from banks or financial institutions on the basis of security of current assets; quarterly returns or statements filed by the Company with such banks or financial institutions are in agreement with the books of account of the Company.

(iii) According to the information and explanations given to us, during the year, the Company has made investments of Rs.196.55 lakhs in Two firms. As, the Company has not provided any guarantee or security or granted any advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties. Hence reporting under clause 3(iii), (iii)(a), (iii)(c), (iii)(d), (iii)(e) and (iii)(f) of the Order are not applicable.

The investments made during the year are in our opinion, prima facie, not prejudicial to the company's interest.

(iv) According to the information and explanations given to us, the Company has not granted any loans, made investment or provided guarantee, which are covered by the provisions of Section 185 and 186 of the Companies Act 2013. Hence, reporting under Clause 3(iv) of the Order is not applicable.

(v) The Company has not accepted any deposits or money deemed to be deposits from the public. Accordingly, Clause 3(v) of the Order is not applicable.

(vi) The Cost records prescribed under Section 148(1) of the Act are not applicable to the Company and hence Clause 3(vi) of the Order is not applicable.


(vii) (a) According to the information and explanations given to us and the records of the Company examined by us, in our opinion, the Company is generally been regular in depositing undisputed statutory dues including Provident Fund, Employees' State Insurance, Income Tax, Sales Tax, Service tax, Custom duty, Excise duty, value added tax, cess and other statutory dues as applicable with the appropriate authorities. There were no undisputed amounts payable in respect of Provident Fund, Employees' State Insurance, Income tax, Sales Tax, Service Tax, Customs Duty, Excise Duty, Value Added Tax, Cess and other material statutory dues in arrears as at March 31, 2023 for a period of more than six months from the date they become payable.



- (b) There were no dues which have not been deposited in respect of Income tax, Sales Tax, Service Tax, Customs Duty, Excise Duty and Value Added Tax on account of any dispute.
- (viii) There were no transactions relating to previously unrecorded income that have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961).
- (ix) (a) The Company has not defaulted in any repayment of loans or other borrowings from or in the payment of interest thereon to any lenders.
- (b) The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.
- (c) The term loan taken by the company is applied for the same purpose for which the loan were obtained.
- (d) On an overall examination of the financial statements of the Company, funds raised on short-term basis have, prima facie, not been used during the year for long-term purposes by the Company.
- (x) Based upon the audit procedures performed and according to the information and explanations given to us, no fraud by the Company or any fraud on the Company by its officer/employees has been noticed or reported during the period nor have we been informed about any such case by the Management.
- (xi) In our opinion and according to information and explanations given to us, the Company has paid/provided remuneration in accordance with requisite approvals mandated by the provisions of section 197 read with schedule V of the Companies Act, 2013.
- (xii) As the Company is not Nidhi Company, the reporting under clause 3(xii) of the Order is not applicable.
- (xiii) In our opinion and according to the information and explanations given to us the Company is in compliance with Section 177 and 188 of the Companies Act, 2013, where applicable, for all transactions with the related parties and the details of related party transactions have been disclosed in the financial statements etc. as required by the applicable accounting standards.




- (xiv) In our opinion and according to the information and explanations given to us, during the year provisions of section 138 relating to Internal Audit System are not applicable to Company, hence, reporting under clause 3(xiv)(a) and (b) of the Order is not applicable.
- (xv) In our opinion and according to the information and explanations given to us, during the year the Company has not entered into any non-cash transactions with its directors or persons connected with him and hence provisions of section 192 of the Companies Act, 2013 are not applicable.
- (xvi) (a) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, the reporting under Clause 3(xvi)(a) of the Order is not applicable to the Company
- (b) The Company has not conducted non-banking financial / housing finance activities during the year. Accordingly, the reporting under Clause 3(xvi)(b) of the Order is not applicable to the Company.
- (c) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, the reporting under Clause 3(xvi)(c) of the Order is not applicable to the Company.
- (xvii) The Company has not incurred cash loss during the current financial year and during the immediately preceding financial year.
- (xviii) There has been no resignation of the Statutory Auditors of the Company during the year.
- (xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any



assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

- (xx) Currently Provisions of Section 135(5) of the Companies Act, relating to Corporate Social Responsibility spending, are not applicable to the Company, hence the reporting under clause 3(xx) of the Order is not applicable.



Place: Mumbai
Dated: August 7th, 2023

For KUMBHAT & CO.
Chartered Accountants
Firm Regn. No. 001609S

A handwritten signature in black ink, appearing to read "Gaurang C. Unadkat".

Gaurang C. Unadkat
Partner

Mem.No. 131708

UDIN: 23131708BGWHGE8783

Annexure "B" to the Independent Auditor's Report

(Referred to in Paragraph 2(f) under the heading of "Report on Other Legal and Regulatory Requirements" of our report of even date)

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **Mono Pharmacare Limited** ("the Company") as of March 31, 2023 in conjunction with our audit of the financial statements of the Company for the period ended on that date.


Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, to the extent applicable to an audit of internal financial controls, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their



operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting


Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion



In our opinion, to the best of information and explanations given to us, the Company has, in all materials respects, an adequate internal financial controls system over financial reporting and such financial controls over financial reporting are operating effectively as at March 31, 2023 based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

Place: Mumbai
Dated: August 7th, 2023



For KUMBHAT & CO.
Chartered Accountants
Firm Regn. No. 001609S

A handwritten signature in blue ink, appearing to read "Gaurang C. Unadkat".

Gaurang C. Unadkat
Partner

Mem.No. 131708

UDIN: 23131708BGWHGE8783

MONO PHARMACARE LIMITED

Balance Sheet as at March 31, 2023

CIN: U24304GJ2022PLC136193

(Rupees in Lakhs)


| | Particulars | Note No. | As at March 31,2023 |
|------------|---|-------------|---------------------|
| I. | EQUITY AND LIABILITIES | | |
| (1) | Shareholders' Funds | | |
| | (a) Share Capital | 2 | 1236.86 |
| | (b) Reserve and surplus | 3 | 103.06 |
| | | | 1339.92 |
| (2) | Non-current liabilities | | |
| | (a) Long-term borrowings | 4 | 343.48 |
| | | | 343.48 |
| (3) | Current Liabilities | | |
| | (a) Short Term Borrowings | 5 | 907.05 |
| | (b) Trade Payables | 6 | |
| | (i) Total outstanding dues of micro enterprises and small enterprises | | 115.01 |
| | (ii) Total outstanding dues of creditors other than micro enterprises and small enterprises | | 94.32 |
| | (c) Other Current Liabilities | 7 | 61.94 |
| | (d) Short-term Provisions | 8 | 44.85 |
| | | | 1223.16 |
| | TOTAL | | 2906.56 |
| II. | ASSETS | | |
| (1) | Non Current Assets | | |
| | (a) Property, Plants & Equipment | 9 | |
| | (i) Tangible Assets | | 19.16 |
| | (b) Non-Current Investments | 10 | 196.55 |
| | (c) Deferred tax assets (Net) | 11 | 5.09 |
| | (d) Long-term loans and advances | 12 | 1.45 |
| | | | 222.25 |
| (2) | Current Assets | | |
| | (a) Inventories | 13 | 1518.12 |
| | (b) Trade Receivables | 14 | 808.39 |
| | (c) Cash and Cash Equivalents | 15 | 22.86 |
| | (d) Short Term Loans and Advances | 16 | 308.67 |
| | (e) Other Current Assets | 17 | 26.27 |
| | | | 2684.31 |
| | TOTAL | | 2906.56 |
| | Significant Accounting Policies | 1 2 - 34 | |

See accompanying notes forming part of the financial statement

For Kumbhat & Co.
Chartered Accountants
FRN: 001609S

Gaurang Unadkat

Gaurang Unadkat
Partner
Membership No. : 131708
Place:- Ahmedabad
Date:- August 7th, 2023



For and on behalf of the Board of Directors
Mono Pharmicare Limited

Panilam S. Lakhatariya
Panilam S. Lakhatariya
Chairman & Managing Director
DIN: 07659275

Neha C Prajapati
Neha C Prajapati
Chief Financial Officer

A. S. Shah
A. S. Shah
Archit Shah
Director
DIN: 09737945

Krupali Thakkar
Krupali Thakkar
Company Secretary

Place: Ahmedabad
Date:- August 7th, 2023

MONO PHARMACARE LIMITED

Statement of Profit and Loss for the period ended on March 31, 2023

CIN: U24304GJ2022PLC136193


(Rupees in Lakhs)

| | Particulars | Note No. | From 06/12/2022 to 31/03/2023 |
|------|--|-------------|----------------------------------|
| I | Revenue from operation | 18 | 1391.61 |
| II | Other income | 19 | 19.73 |
| III | Total Revenue (I + II) | | 1411.35 |
| IV | Expenses | | |
| | Purchase of Traded Goods | 20 | 2015.26 |
| | (Increase)/Decrease in Stock | 21 | -827.07 |
| | Employee Benefits Expenses | 22 | 59.53 |
| | Finance Cost | 23 | 37.79 |
| | Depreciation and Amortisation Cost | 9 | 2.25 |
| | Other expenses | 24 | 57.01 |
| | Total Expenses | | 1344.76 |
| V | Profit before tax Extraordinary and Exceptional Items (III - IV) | | 66.59 |
| VI | Exceptional Items | | 0.00 |
| VII | Extraordinary Items And Tax (V- VI) | | |
| | Prior Period Expenses | | 0.00 |
| VIII | Profit Before Tax | | 66.59 |
| IX | Tax Expenses | | |
| | (1) Current Tax | | 17.50 |
| | (2) Deferred Tax | | -5.09 |
| X | Profit (Loss) for the Year | | 54.18 |
| XI | Earning per Equity share : | 30 | |
| | (1) Basic | | 0.55 |
| | (2) Diluted | | 0.55 |
| | Significant Accounting Policies | 1 2 - 34 | |

See accompanying notes forming part of the financial statement

For Kumbhat & Co.
Chartered Accountants
FRN: 001609S

For and on behalf of the Board of Directors
Mono Pharmacare Limited



Gaurang Unadkat
Partner
Membership No. : 131708

Panilam S. Lakhatariya
Panilam S. Lakhatariya
Chairman & Managing Director
DIN: 07659275

Neha C Prajapati
Neha C Prajapati
Chief Financial Officer

A.S. Shah
Archit Shah
Director
DIN: 09737945

Krupali Thakkar
Krupali Thakkar
Company Secretary

Place:- Ahmedabad
Date:- August 7th, 2023

Place: Ahmedabad
Date:- August 7th, 2023

MONO PHARMACARE LIMITED

Cash Flow Statement statement for the period ended on March 31, 2023

CIN: U24304GJ2022PLC136193

| | March 31, 2023 |
|---|--------------------------|
| | (Rupees in Lakhs) |
| Cash flow from operating activities | |
| Profit/(loss) before tax | 66.59 |
| Non-cash adjustments to reconcile profit before tax to net cash flows | |
| Depreciation | 2.25 |
| Finance Cost | 37.79 |
| Operating profit/(loss) before working capital changes | 106.62 |
| Movements in working capital: | |
| Increase/(decrease) in trade payables | 209.33 |
| Increase/(decrease) in other current liabilities | 61.94 |
| Increase/(decrease) in short term provision | 27.35 |
| Increase/(decrease) in short term borrowings | 907.05 |
| Decrease/(increase) in Inventories | -1518.12 |
| Decrease/(increase) in trade receivables | -808.39 |
| Decrease/(increase) in short-term loans and advances | -308.67 |
| Decrease/(increase) in other Current Assets | -26.27 |
| Cash generated from Operations | -1349.17 |
| Less: Direct taxes paid | |
| Net Cash from Operating Activities (A) | -1349.17 |
| Cash flows from investing activities | |
| Sale/(Purchase) of Fixed Assets | -21.41 |
| Purchase of Investment | -196.55 |
| Net cash flow from/(used in) investing activities (B) | -217.96 |
| Cash flow from financing activities | |
| Acceptance / (Repayment) of Long Term Loan | 343.48 |
| Payment / (Repayment) of Long term Loan advance | -1.45 |
| Proceeds from issue of equity shares | 1285.74 |
| Finance Cost | -37.79 |
| Net cash flow from/(used in) financing activities (C) | 1589.99 |
| Net increase/(decrease) in cash and cash equivalents (A+B+C) | 22.86 |
| Cash and cash equivalents at the beginning of the year | 0.00 |
| Cash and cash equivalents at the end of the year | 22.86 |
| Net increase/(decrease) in cash and cash equivalents | 22.86 |

See accompanying notes forming part of the financial statement

For Kumbhat & Co.

Chartered Accountants

FRN: 001609S



Gaurang Unadkat
Partner

Membership No. : 131708

Place:- Ahmedabad

Date:- August 7th, 2023

For and on behalf of the Board of Directors
Mono Pharmacare Limited

Panilam
Panilam S. Lakhatariya
Chairman & Managing Director
DIN: 07659275

Neha
Neha C Prajapati
Chief Financial Officer

Place: Ahmedabad

Date:- August 7th, 2023

A.S. Shah

Archit Shah
Director

DIN: 09737945

Krupali Thakkar
Krupali Thakkar
Company Secretary

MONO PHARMACARE LIMITED
Notes forming part of the Financial Statement
CIN: U24304GJ2022PLC136193

(Rupees in Lakhs)

| Particulars | As at March 31, 2023 | |
|--|----------------------|--|
| NOTE 2: SHARE CAPITAL | | |
| Authorised Share Capital | | |
| 2,00,00,000 Equity Shares of Rs. 10/- each. | 2000.00 | |
| Issued Subscribed and paid up Share Capital | | |
| 1,23,68,564 Equity Shares of Rs. 10/- each. | 1236.86 | |
| | 1236.86 | |

NOTE 2.1: Reconciliation of No. of shares Outstanding at the beginning & at the end of the reporting period

| | As at March 31, 2023 | |
|--|----------------------|----------------|
| | No. | Rs. |
| At the beginning of the period | 100,000 | 10.00 |
| Add: Equity Shares allotted against the partners' Capital | 4,313,650 | 431.37 |
| Add: Preferential allotment of Equity Shares during the period | 5,081,699 | 508.17 |
| Add: Right issue of Equity Shares during the period | 2,345,695 | 234.57 |
| Add: Bonus Shares issued during the period | 527,520 | 52.75 |
| Outstanding at the end of the year | 12,368,564 | 1236.86 |

NOTE 2.2: The details of shareholders holding of more than 5% of the aggregate shares of the Company


| Name of the Shareholders | As at March 31, 2023 | |
|---|----------------------|-------------|
| | No. of Shares held | % |
| Panilam Shivilal Lakhatariya (Promoter) | 8,026,761 | 64.90% |
| Supal Panilam Lakhatariya (Promoter) | 1,993,458 | 16.12% |
| Others | 2,348,345 | 18.99% |
| Total | 12,368,564 | 100% |

Terms/Rights to Equity Shares

- (a) The company has only one class of shares i.e. Equity Share
(b) All equity shares rank pari-pasu and carry equal right respect to voting and dividend. In the event of liquidation of the company the equity shares holder shall be entitled to proportionate share of their holding in the assets remaining after distribution of all preferential amounts.
(c) Out of the above, 99,22,869 equity Shares of Face Value Rs. 10/- each were issued for consideration other than cash.

NOTE 3: RESERVES & SURPLUS

| | | |
|---|--|---------------|
| Security premium | | |
| Add: On Preferential allotment of Equity Shares during the period | | 101.63 |
| Less: Utilised for Bonus Shares issued during the period | | -52.75 |
| | | 48.88 |
| Profit and Loss Account | | |
| Opening balance | | - |
| Add : Profit during the period | | 54.18 |
| Balance at the end of the year | | 54.18 |
| | | 103.06 |




MONO PHARMACARE LIMITED
Notes forming part of the Financial Statement
CIN: U24304GJ2022PLC136193

(Rupees in Lakhs)

| Particulars | As at March 31, 2023 | | | | | | | | | |
|---|----------------------|---------------------------------|--|--|----------------------|----------------------|---------------------------------|-----------------|----------------|----------------|
| NOTE 4: LONG-TERM BORROWINGS | | | | | | | | | | |
| Secured Loan | | | | | | | | | | |
| Working Capital Demand Loan | | | | | | | | | | |
| (a) From Banks | 123.92 | | | | | | | | | |
| | 123.92 | | | | | | | | | |
| <p>Bank of India: Secured against the hypothecation of Stock and Book Debts and Mortgage against the Residential flat No. B 703 and 704, and C- 603, Shyam Elegance, Anandnagar Cross Road, Vastrapur Railway Station Road, Jodhpur, Ahmedabad Pin 380015 owned Mrs. Supal Panilam Lakhtariya and Pledging of TDR in the name of Mr. Panilam Lakhtariya of Rs. 30.00 lacs</p> <p>Deutsche Bank: Secured against the Mortgage against the Residential Banglow no 8, Ravji Emerald co. op. soc., Opp. Bopal Police Chowki, Gala Gymkhana Road, Bhopal, Ahmedabad Pin 380015 owned Mr. Panilam Lakhtariya</p> <p>(The above includes loan taken from Bank of India and Deutsche Bank having interest rate on such loans are 8.75% and 7.10%, and those are repayable between period of 2-3 years and 15 Years respectively. The above loan is classified as Current and Non-current based on the original tenure of the loan.</p> <p>Maturity profile of secured loan are set out as below:</p> <table style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th colspan="3" style="text-align: center;">Maturity Profile</th> </tr> <tr> <th style="text-align: center;">1st Year</th> <th style="text-align: center;">2nd year</th> <th style="text-align: center;">3rd Year & above</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">Rs. 25,15,304/-</td> <td style="text-align: center;">Rs.27,23,108/-</td> <td style="text-align: center;">Rs.96,69,319/-</td> </tr> </tbody> </table> | | Maturity Profile | | | 1 st Year | 2 nd year | 3 rd Year & above | Rs. 25,15,304/- | Rs.27,23,108/- | Rs.96,69,319/- |
| Maturity Profile | | | | | | | | | | |
| 1 st Year | 2 nd year | 3 rd Year & above | | | | | | | | |
| Rs. 25,15,304/- | Rs.27,23,108/- | Rs.96,69,319/- | | | | | | | | |
| Unsecured Loan : | | | | | | | | | | |
| Working Capital Demand Loan | | | | | | | | | | |
| (a) From Banks | 11.34 | | | | | | | | | |
| (b) From Financial Institution | 3.21 | | | | | | | | | |
| (c) From Director & relatives | 205.01 | | | | | | | | | |
| | 343.48 | | | | | | | | | |

(Unsecured Loan is taken from various Banks and Financial Institution and interest rate is between 18% to 20% which is repayable between period of 3 years to 15 years and the same has been classified as Current and Non-current based on the original tenure of the loan)



MONO PHARMACARE LIMITED
Notes forming part of the Financial Statement
CIN: U24304GJ2022PLC136193

(Rupees in Lakhs)

Particulars

As at March 31, 2023

NOTE 5 :- SHORT TERM BORROWINGS

Secured Loan

From Banks

(a) Cash Credit

839.28

Bank of India: Secured against the hypothecation of Stock and Book Debts and Mortgage against the Residential flat No. B 703 and 704, and C- 603, Shyam Elegance, Anandnagar Cross Road, Vastrapur Railway Station Road, Jodhpur, Ahmedabad Pin 380015 owned Mrs. Supal Panilam Lakhtariya and Pledging of TDR in the name of Mr. Panilam Lakhtariya of Rs. 30.00 lacs

Cosmos Bank: Hypothecation Charge on all current assets of firm and Mortgage of Immovable Property Residential flat No. C 701 and 702, Shyam Elegance, Mouje: Vejalpur, Ahmedabad and Secured against the Residential flat 403-B, Palmera, Vadsar, Vododara owned by Mr. Panilam Shivilal Lakhatraiya.

(b) Working Capital Demand Loan

25.15

Bank of India: Secured against the hypothecation of Stock and Book Debts and Mortgage against the Residential flat No. B 703 and 704, and C- 603, Shyam Elegance, Anandnagar Cross Road, Vastrapur Railway Station Road, Jodhpur, Ahmedabad Pin 380015 owned Mrs. Supal Panilam Lakhtariya and Pledging of TDR in the name of Mr. Panilam Lakhtariya of Rs. 30.00 lacs

Deutsche Bank: Secured against the Mortgage against the Residential Banglow no 8, Ravji Emerald co. op. soc., Opp. Bopal Police Chowki, Gala Gymkhana Road, Bhopal, Ahmedabad Pin 380015 owned Mr. Panilam Lakhtariya

(The above includes loan taken from Bank of India and Deutsche Bank having interest rate on such loans are 8.75% and 7.10%, and those are repayable between period of 2-3 years and 15 Years respectively. The above loan is classified as Current and Non-current based on the original tenure of the loan.

Maturity profile of secured loan are set out as below:

Maturity Profile

| 1 st Year | 2 nd year | 3 rd Year & above |
|----------------------|----------------------|---------------------------------|
| Rs. 25,15,304/- | Rs.27,23,108/- | Rs.96,69,319/- |

UnSecured Loan

Working Capital Demand Loan

From Banks

19.67


From Financial Institution

22.94

(Unsecured Loan is taken from various Banks and Financial Institution and interest rate is between 18% to 20% which is repayable between period of 3 years to 15 years and the same has been classified as Current and Non-current based on the original tenure of the loan)

Maturity Profile

| 1 st Year | 2 nd year | 3 rd Year & above |
|----------------------|----------------------|---------------------------------|
|----------------------|----------------------|---------------------------------|



MONO PHARMACARE LIMITED
Notes forming part of the Financial Statement
CIN: U24304GJ2022PLC136193

(Rupees in Lakhs)

| Particulars | As at March 31, 2023 |
|---|----------------------|
| Rs. 42,61,352/- Rs.14,54,957/- Rs.Nil | 907.05 |

NOTE 6 :- TRADE PAYABLES

For goods and Services

| | |
|--|---------------|
| Total outstanding dues of micro enterprises and small enterprises | 115.01 |
| Total outstanding dues of creditors other than micro enterprises and small enterprises | 94.32 |
| Total | 209.33 |

Outstanding for following periods from due date of payment

| Particulars | Less than 1 year | 1 to 2 years | 2 to 3 years | More than 3 years | Total |
|----------------------|------------------|--------------|--------------|-------------------|--------------|
| MSME | 115.01 | 0.00 | 0.00 | 0.00 | 115.0 |
| Others | 94.32 | 0.00 | 0.00 | 0.00 | 94.3 |
| Disputed dues-MSME | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 |
| Disputed dues-Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 |

NOTE 7 :- OTHER CURRENT LIABILITIES

Other Current Liabilities

| | |
|-----------------------------|--------------|
| Salary Payable | 14.96 |
| Statutory dues Payable | 9.68 |
| Interest Payable | 0.37 |
| Advance recd from Customers | 36.93 |
| | 61.94 |

NOTE 8 :- SHORT TERM PROVISIONS


| | |
|---|--------------|
| Provision for Gratuity | 2.63 |
| Provision for Tax (Net off advance tax) | 42.22 |
| Total | 44.85 |



MONO PHARMACARE LIMITED
NOTE 9 :- PROPERTY, PLANT AND EQUIPMENTS
CIN: U24304GJ2022PLC136193

(Rupees in Lakhs)

| PARTICULARS | GROSS BLOCK | | | | DEPRECIATION | | | | NET BLOCK | |
|-------------------|-------------------|-------------|-------------|--------------|-------------------|-------------------|-------------|-------------|---------------------|---------------------|
| | AS ON 06/12/22 | ADDITION | DEDUCTION | TOTAL | AS ON 06/12/22 | FOR THE PERIOD | DEDUCTION | TOTAL | AS ON 31/03/2023 | AS ON 06/12/2022 |
| FURNITURE | 6.23 | 1.23 | | 7.46 | 0.00 | 0.58 | 0.00 | 0.58 | 6.88 | 0.00 |
| OFFICE EQUIPMENTS | 4.07 | 2.06 | | 6.13 | 0.00 | 0.76 | 0.00 | 0.76 | 5.37 | 0.00 |
| COMPUTERS | 0.45 | 3.17 | | 3.63 | 0.00 | 0.53 | 0.00 | 0.53 | 3.10 | 0.00 |
| VEHICLE | 2.21 | 1.99 | | 4.20 | 0.00 | 0.37 | 0.00 | 0.37 | 3.82 | 0.00 |
| TOTAL | 12.96 | 8.44 | 0.00 | 21.41 | 0.00 | 2.25 | 0.00 | 2.25 | 19.16 | 0.00 |




MONO PHARMACARE LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENT
CIN: U24304GJ2022PLC136193

(Rupees in Lakhs)

| | As at March 31, 2023 |
|---|-------------------------|
| <u>NOTE 10 :- NON-CURRENT INVESTMENTS</u> | |
| Investment in Partnership firms | 196.55 |
| | 196.55 |
| <u>NOTE 11 :- DEFERRED TAX ASSET/LIABILITIES</u> | |
| Deferred Tax Assets | |
| on account of Depreciation on Fixed Assets | 0.17 |
| on account of Provision for Gratuity | 0.66 |
| On account of other temporary disallowance | 4.25 |
| | 5.09 |
| <u>NOTE 12 :- Long-term loans and advances</u> | |
| Security Deposits | 1.45 |
| | 1.45 |
| <u>NOTE 13 :- INVENTORIES</u> | |
| Stock in trade | 1518.12 |
| | 1518.12 |
| <u>NOTE 14 :- TRADE RECEIVABLES</u> | |
| <u>Unsecured, Considered Good</u> | |
| Over six months from the due date | 436.84 |
| Others | 371.54 |
| | 808.39 |

Outstanding for following periods from due date of payment

| Particulars | Less than 6 | 6 months to 1 year | 1 to 2 years | 2 to 3 years | More than 3 years | Total |
|--|----------------|-----------------------|--------------|--------------|----------------------|---------------|
| Undisputed trade receivables - considered good | 371.54 | 411.63 | 1.29 | 0.00 | 0.00 | 784.46 |
| Undisputed trade receivables - credit impaired | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Disputed trade receivables - considered good | 0.00 | 23.93 | 0.00 | 0.00 | 0.00 | 23.93 |
| Disputed trade receivables - credit impaired | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |




MONO PHARMACARE LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENT
CIN: U24304GJ2022PLC136193

(Rupees in Lakhs)

As at March 31,
2023

| | |
|--|---------------|
| <u>NOTE 15 :- CASH AND CASH EQUIVALENT</u> | |
| Cash in Hand | 0.26 |
| <u>Balances with Banks</u> | |
| Balances in Current Accounts | 8.36 |
| Fixed / Recurring Deposit with Bank | 14.24 |
| Total | 22.86 |
| <u>NOTE 16 :- SHORT TERM LOANS AND ADVANCES</u> | |
| Security Deposits | 0.68 |
| Advance to Suppliers | 204.37 |
| Other advances | 103.62 |
| Total | 308.67 |
| <u>NOTE 17 :- OTHER CURRENT ASSETS</u> | |
| IPO Expenses | 1.50 |
| Advances to Employees | 4.38 |
| Balance with Revenue Authorities | 20.39 |
| Total | 26.27 |



MONO PHARMACARE LIMITED
NOTES TO THE FINANCIAL STATEMENT
CIN: U24304GJ2022PLC136193

(Rupees in Lakhs)

| Particulars | For the period ended March 31, 2023 |
|---|--|
| <u>NOTE 18 :- REVENUE FROM OPERATIONS</u> | |
| <u>Sales</u> | |
| - Sale of Goods | 1391.61 |
| Total | 1391.61 |
| <u>NOTE 19 :- OTHER INCOME</u> | |
| Commission Income | 0.13 |
| Interest on Fixed deposit | 0.26 |
| Profit From Partnership Firm | 18.57 |
| Sales Cum Promotion Income | 0.76 |
| Total | 19.73 |
| <u>NOTE 20 :- PURCHASE OF TRADED GOODS</u> | |
| <u>Purchases</u> | |
| Purchase of Goods | 2033.99 |
| Less: Purchase return | 18.73 |
| Total | 2015.26 |
| <u>NOTE 21 :- INCREASE/(DECREASE) IN STOCK</u> | |
| Closing Stock | 1518.12 |
| Opening Stock | 691.05 |
| Total | -827.07 |
| <u>NOTE 22 :- EMPLOYEE BENEFITS EXPENSES</u> | |
| Salary Expenses | 42.56 |
| Director Remuneration | 9.60 |
| Staff Welfare Expenses | 0.83 |
| Gratuity | 2.63 |
| ESI | 0.98 |
| Provident fund | 2.93 |
| | 59.53 |



MONO PHARMACARE LIMITED
NOTES TO THE FINANCIAL STATEMENT
CIN: U24304GJ2022PLC136193

(Rupees in Lakhs)

| Particulars | For the period ended March 31, 2023 |
|---|--|
| <u>NOTE 23 :- FINANCE COST</u> | |
| Interest Paid | 36.04 |
| Bank Charges | 0.22 |
| Processing Fees | 1.53 |
| | 37.79 |
| <u>NOTE 24 :- OTHER EXPENSES</u> | |
| Audit Fees | 2.00 |
| Business Promotion Expenses | 7.95 |
| Consultancy Expenses | 0.92 |
| Conveyance Expenses | 5.59 |
| Charity Expenses | 0.74 |
| Cylinder Charges | 0.47 |
| Electricity Expenses | 0.64 |
| Interest On Tds | 0.02 |
| Miscellaneous Expenses | 0.35 |
| Professional fees | 3.02 |
| Rates and Taxes | 21.24 |
| Legal Expenses | 0.41 |
| Loss on sale Fixed Assets | 0.15 |
| Telephone Expenses | 0.46 |
| Office Expenses | 1.04 |
| Packing Expenses | 1.07 |
| Postage & Courier Expenses | 0.79 |
| Printing & Stationery | 3.37 |
| Rent Expenses | 3.24 |
| Repairs & Maintenance | 0.17 |
| ROC Exp | 0.15 |
| Software Expenses | 0.69 |
| Transportation Expenses | 0.30 |
| Travelling Expenses | 2.24 |
| | 57.01 |



Note 1: Significant Accounting policies to the Restated Financial Statements

Annexure 1.1: Corporate Information:

The Company was originally formed at Partnership Firm in the name and style of **M/s. Mono Chemist**. The firm was converted from Partnership firm into Limited Company with the name of **Mono Pharmacare Limited** with effect from 17th October, 2022 vide CIN U24304GJ2022PLC136193. The Company is engaged in the business of distribution of Pharmaceutical items.

Place of business:

The place of business of the Company is at 1A, Krinkal Apartment Opp. Mahalaxmi Temple, Paldi Ahmedabad Gujarat 380007.

Annexure 1.2: Significant Accounting Policies:

The significant accounting policies followed by the company are stated as below:

i. Basis of preparation of financial statements

- a. The financial statements are prepared under the historical cost convention, in accordance with applicable accounting standards specified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and the relevant provision of the Companies Act, 2013.
- b. The accounts have been prepared on a going concern basis under historical cost convention.
- c. Accounting policies not specifically referred to otherwise are in consonance with generally accepted accounting principles followed by the Company.

ii. Use of estimates

The preparation of financial statements in conformity with Generally Accepted Accounting Principles requires estimates and assumptions to be made that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities on the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those



estimates and differences between actual results and estimates are recognised in the periods in which the results are known / materialise.

iii. Property, Plant and Equipment

- a. Fixed assets are carried at cost of acquisition less accumulated depreciation.
- b. The cost of fixed assets comprises the purchase price (net of rebates and discounts) and any other directly attributable costs of bringing the assets to their working condition for their intended use.

iv. Depreciation:

- a. Depreciation on fixed assets is being provided on Written down value method as per the useful life prescribed in Schedule II of the Companies Act, 2013.
- b. Depreciation in respect of addition to fixed assets is provided on pro-rata basis from month to month in which such assets acquired/installed.
- c. Depreciation on fixed assets sold, discarded or demolished during the year is being provided at their respective rate upto the month in which such assets are sold, discarded or demolished.

v. Investments

Investments are Long-term, unless stated otherwise and are stated at cost except where there is diminution in value other than temporary, in which case a provision is made to the carrying value to recognize the diminution.


vi. Taxation:

a. Current tax:

Provision for current tax is made on the estimated taxable income at the rate applicable to the relevant assessment year.

b. Deferred tax:

Deferred tax charge or benefit reflects the tax effects of timing differences between accounting income and taxable income, which originate during the year but reverse in subsequent years.



The deferred tax charge or credit and the corresponding deferred tax liabilities or assets are recognised using the tax rates that have been enacted or substantially enacted by the balance sheet date.

vii. Revenue Recognition:

- Sales of pharmacy products are exclusive of GST and are stated net of discounts. Sale of pharmacy products is recognized when risk and rewards of ownership of the products are passed on to the customers, which is generally on dispatch of goods. Returns against sales and price difference are recognized as and when ascertained and are netted from the amount of sales for the year.

viii. Borrowing Cost:

Borrowing costs include interest, amortization of ancillary costs incurred and exchange differences arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost. Costs in connection with the borrowing of funds to the extent not directly related to the acquisition of qualifying assets are charged to the Statement of Profit and Loss over the tenure of the loan.

Borrowing costs, allocated to and utilized for qualifying assets, pertaining to the period from commencement of activities relating to construction / development of the qualifying asset up to the date of capitalization of such asset is added to the cost of the assets.


Capitalization of borrowing costs is suspended and charged to the Statement of Profit and Loss during extended periods when active development activity on the qualifying assets is interrupted.

ix. Current & Non Current Classification:

All assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle and other criteria set-out in the Act. Deferred tax assets and liabilities are classified as non-current assets and non-current liabilities, as the case may be.

x. Inventories:

Inventories are valued at the lower of cost (Generally determined on FIFO basis) and Net realizable value. Cost includes all charges in bringing the goods to the point of sale, including octroi and other levies, transit insurance and receiving charges.



xi. Provisions and Contingencies:

- a. A provision is recognised when there is a present obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligation, in respect of which a reliable estimate can be made. Provisions are not discounted to its present value and are determined based on management best estimates of the expenditure required to settle the obligation as at the balance sheet date. Provisions are reviewed at each balance sheet date and adjusted to reflect the current best estimate of each such obligation.
- b. A contingent liability is disclosed when there is a possible or present obligation that may, but probably will not require an outflow of resources, unless the possibility of such outflow is remote.
- c. Contingent Assets are neither recognised nor disclosed.


xii. Cash Flow Statement

The Cash Flow Statement is prepared by the indirect method set out in Accounting Standard 3 on Cash Flow Statements and presents the cash flows by operating, investing and financing activities of the Company.

Cash and Cash equivalents presented in the Cash Flow Statement consist of cash on hand and unencumbered bank balances and Fixed Deposit with the banks which are short term.

xiii. Earnings per Share:

Basic earning per share is computed by dividing the net profit after tax attributable to equity shareholders for the year by the weighted average number of equity shares outstanding during the year. Diluted earning per share is computed by dividing the net profit after tax attributable to equity shareholders for the year by the weighted average number of equity shares outstanding during the year as adjusted for the effects of all dilutive potential equity shares, if any.



25. During the year, the Company has acquired the running business of DLS Export, Proprietary concern of Mr Panilam Lakhtariya as on December 15th, 2022 of Rs.6,09,80,385/- and in consideration the Company has issued 50,81,699 number of Equity shares of Rs. 12 each.

26. During the Year, the Company has acquired the 99% capital each into partnership firm named as below:

| Sr. No. | Name of the entities acquired | % of capital acquired | Date of acquisition | Amount paid |
|---------|--|-----------------------|---------------------|--------------|
| 1 | Ahmedabad Medical Corporation Investment | 99.00% | 01/02/2023 | Rs.9,99,000/ |
| 2 | Supal Distributors LIP Investment | 99.00% | 01/02/2023 | Rs.99,900/ |

27. Related Parties Transactions

As per Accounting Standard 18, the disclosures of transactions with the related parties are as under:

A. Directors of the Company:

1. Panilam Shivlal Lakhatariya - Managing Director
2. Supal Panilam Lakhatariya - Director
3. Archit Shah - Executive Director
4. Mitul Sapara - Non - Executive Director
5. Chintan Trivedi - Independent director
6. Gaurang Vora - Independent director

B. Key Management Personnel:


1. Panilam Shivlal Lakhatariya Director
2. Supal Panilam Lakhatariya Director
3. Krupali R. Thakkar Company Secretary (w.e.f. Appointment date 26/12/2022)
4. Mrs. Neha Prajapati - Chief Financial Officer

C. Relatives of the Director/s:

1. Supal Panilam Lakhatariya Wife of Mr. Panilam Lakhatariya
2. Archit Shah Brother of Mrs. Supal Lakhatariya

D. Enterprise over which Directors is having significant influence:

1. Supal Medical & Wholesale LLP
2. Supal Pharma
3. R.B. Agencies
4. Supal Trading LLC
5. Stylemantraas Private Limited



D. Enterprise over which Directors is having significant influence:

1. Supal Medical & Wholesale LLP
2. Supal Pharma
3. R.B. Agencies
4. Supal Trading LLC
5. Stylemantraas Private Limited
6. Panilam Lakhatariya HUF

E. Subsidiaries Entities

1. Ahmedabad Medical Corporation,
2. Supal Distributors LLP

The following transactions were carried out with the related parties in the ordinary course of business (except reimbursement of actual expenses)


(Rupees in Lakhs)

| Particulars | Nature of Transaction | For the period ended on 31/03/2023 |
|---------------------------------|------------------------------|---|
| A. Key Managerial Person | | |
| 1. Panilam Shivilal Lakhatariya | Remuneration | 4.00 |
| | Loan Taken | 0.00 |
| | Loan Repaid | 0.00 |
| | Share Allotment | 866.29 |
| 2. Supal Panilam Lakhatariya | Remuneration | 4.00 |
| | Sales | 0.00 |
| | Share Allotment | 194.35 |
| | Loan Taken | 34.18 |
| | Loan Repaid | 17.77 |
| 3. Archit Shah Current Capital | Remuneration | 1.60 |
| | Loan taken | 0.20 |
| | Share Allotment | 0.05 |
| 4. Pallaviben Shah | Loan taken | 0.20 |
| | Share Allotment | 0.05 |
| 5. Shardaben Lakhatariya | Loan taken | 0.20 |
| | Share Allotment | 0.05 |
| 6. Shivam Chauhan | Loan taken | 0.20 |



| | | |
|---|---------------------------|--------|
| | Share Allotment | 0.05 |
| 7. Shivlal Lakhatariya Current Capital | Loan taken | 0.20 |
| | Share Allotment | 0.05 |
| B. Subsidiaries | | |
| 1. Supal Distributors LLP | | 0.00 |
| | Loan Repiad | 0.00 |
| | Sales | 339.74 |
| | Purchase | 309.99 |
| | Investment | 0.99 |
| | Profit Received from firm | 8.88 |
| 2. Ahmedabad Medical Corporation | Sales | 114.04 |
| | Purchase | 238.95 |
| | Investment | 176.99 |
| | Profit Received from firm | 9.69 |
| C. Transactions with entities wherein Key Managerial Personnel have significant influence: | | |
| 1. Panilam Shivlal Lakhatariya HUF | Loan Taken | 0.00 |
| | Loan Repaid | 4.92 |
| 2. Supal Pharma | Sales | 256.81 |
| | Purchase | 137.35 |
| 3. Supal Medical & Wholesale LLP | Sales | 171.66 |
| | Purchase | 138.96 |
| 4. RB Agencies(s) | Sales | 8.78 |

| Balance outstanding | Nature of Transaction | For the period ended on 31/03/2023 |
|-------------------------------------|-----------------------|------------------------------------|
| A. Key Managerial Person | | |
| 1. Panilam Lakhatariya | Loan from Director | 0.00 |
| 2. Supal Lakhatariya | Loan from Director | 204.01 |
| 3. Archit Shah | Loan from Director | 0.20 |
| 4. Pallaviben Shah | Loan from Director | 0.20 |
| 5. Shardaben Lakhatariya | Loan from Director | 0.20 |
| 6. Shivam Chauhan | Loan from Director | 0.20 |
| 7. Shivlal Lakhatariya | Loan from Director | 0.20 |
| B. Subsidiaries | | |
| 1. Supal Distributors LLP | Sales & Purchase | -0.84 |
| | Investment | 9.87 |
| 2. Ahmedabad Medical Corporation(S) | Sales & Purchase | 81.78 |



| | Investment | 186.69 |
|---|------------|--------|
| C. Transactions with entities wherein Key Managerial Personnel have significant influence: | | |
| 1. Panilam Shivilal Lakhatariya HUF | Loan | 0.00 |
| 2. Supal Pharma | Sales | -29.00 |
| 3. Supal Medical & Wholesale LLP | Purchase | 29.61 |
| 4. RB Agencies | Sales | -1.85 |

28. The company does not allow accumulation of leaves and hence the Company has not obtained actuarial valuation report for leave encashment.

The particulars as required under the Accounting Standard-AS 15 of Employees Benefits are as under:

i. Defined Contribution Plan:


| | For the year ended March 31,2023 |
|--|-------------------------------------|
| Contribution to Employees Provident Fund | Rs.2,93,120/- |

ii. Defined Benefit Plan:

The Company has made a gratuity provision as per the Payment of gratuity Act, 1972 of Rs.2,40,363/- obtain from Pankaj Murawala, Labour Consultant and Advocate and has not obtain the actuarial valuation report from actuaries.

29. Dues to Micro & Small Enterprises:

| Particulars | For the year ended March 31,2023 |
|--|-------------------------------------|
| The principal amount and the interest due thereon remaining unpaid to any supplier as at the end of each accounting year | |
| - Principal amount due to micro and small enterprises | 115.01 |
| The amounts of payments made to micro and small suppliers beyond the | - |



| | |
|--|--|
| appointed day during each accounting year. | |
|--|--|

On the basis of information and records available with the company, the above disclosures are made in respect of amounts due to the micro and small enterprises, who have registered with the relevant competent authorities.

30. Earnings per share:

The calculations of earnings per share (basic and diluted) are based on the earnings and number of shares as computed below:

| | For the year ended March 31, 2023 |
|-------------------------------|--------------------------------------|
| Profit/(Loss) after Tax | 54.18 |
| Weighted no. of equity shares | 34,37,765 |
| Earnings per share | |
| - Basic | 0.55 |
| - Diluted | 0.55 |

31. Deferred Taxation:

(Rs. in Lacs)


| | Items of Timing Difference | Accumulated Deferred Tax (Asset) / Liability as on April 1, 2022 | Charge/ (credit) for the year | Accumulated Deferred Tax (Asset)/ Liability as on March 31, 2023 |
|----------------------------|----------------------------------|---|----------------------------------|--|
| Deferred Tax Assets | | | | |
| i. | WDV of Depreciable assets | - | 0.17 | 0.17 |
| ii | Gratuity | - | 0.66 | 0.66 |
| iii | Other | - | 4.25 | 4.25 |
| Net Deferred Tax | | - | 5.09 | 5.09 |



32. Disclosures of Accounting Ratios:

| | Particulars | Formula for Computation | Measures (in times / percentage) | For the Year Ended 31 Mar 2023 |
|---|---|--|--|--------------------------------------|
| A | Current Ratio | Current assets / Current liabilities | Times | 2.19 |
| B | Debt Equity Ratio | Debt / Net worth | Times | 0.93 |
| C | Debt Service Coverage Ratio | EBITDAE / (Finance costs + Principal repayment of long term borrowings within one year) | Times | 0.11 |
| D | Return on Equity | Profit after tax / Net worth | Percentage | 4.04% |
| E | Inventory Turnover Ratio | Cost of goods sold / Average inventory | Times | 1.33 |
| F | Trade Receivable Turnover Ratio | [Revenue from Sales of products (including excise duty) + Sales of services] / Average gross trade receivables | Times | 1.72 |
| G | Trade Payable Turnover Ratio | Purchases / Average trade payables | Times | 9.63 |
| H | Net Capital Turnover Ratio | Revenue from operations / working capital | Times | 0.95 |
| I | Net Profit Ratio | Profit after tax / Revenue from operations | Percentage | 3.89% |
| J | Return on Capital Employed (ROCE) | EBIT / Capital employed | Percentage | 6.20% |
| K | Return on Investment (ROI) | Net Return / Cost of Investment | Percentage | 0.09 |
| Notes | | | | |
| 1 | Debt = Non-current borrowings + Current borrowings | | | |
| 2 | Net worth = Paid-up share capital + Reserves created out of profit+ Security premium - Accumulated losses | | | |
| 3 | Cost of goods sold = Cost of materials consumed + Purchase of stock-in-trade + Changes in inventories of | | | |
| 4 | Purchase = Purchase of stock-in-trade + Purchase of Raw Material and packing material | | | |
| 5 | Working Capital = Current assets - Current liabilities | | | |
| 6 | EBIT = Earnings before Interest, tax and exceptional items | | | |
| 7 | Capital employed = Total equity + Non-current borrowings | | | |
| Note: Since the change in ratio is less than 25%, no explanation is required to be disclosed. | | | | |

33. Debtors & Creditors balances are subject to confirmation. Adjustments, if any, will be made in the accounts on the receipt of such confirmations.




34. In the opinion of the Board, current assets, loans and advances have a value on realization at least equal to the amount at which they are stated in the accounts.


As per our attached report of even date

For and on behalf of the Mono Pharmacare Limited

For Kumbhat & Co.
Chartered Accountants




Gaurang C. Unadkat
Partner
Membership No. 131708




Panilam S Lakhatariya
Chairman & Managing Director
DIN:07659275



Archit Shah
Director
DIN: 09737945



Neha C Prajapati
Chief Financial Officer



Krupali Thakkar
Company Secretary

Place : Ahmedabad
Date : August 7th, 2023

Place : Ahmedabad
Date : August 7th, 2023